Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 2Unknown 1

Sponsor Class

OTHER 61NETWORK 3INDUSTRY 2UNKNOWN 1OTHER_GOV 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 1

Interventions

apatinib 25Cisplatin 19Capecitabine 17Irinotecan 16Cyclophosphamide 15fludarabine 13Radiotherapy 12Oxaliplatin 12camrelizumab 11Paclitaxel 11Drug Therapy 11S 1 (combination) 10Carboplatin 10Fluorouracil 9Docetaxel 9Blood Specimen Collection 9Bevacizumab 9Radiation 7Pemetrexed 7Nivolumab 7Gemcitabine 7Erlotinib Hydrochloride 7tislelizumab 6Surgical Procedures, Operative 6Neoadjuvant Therapy 6Albumin-Bound Paclitaxel 6toripalimab 5XELOX 5Tamoxifen 5Propranolol 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × OTHER_GOV × Lenalidomide × Clear all
NCT04326296 2020-05-15

The Safety and Tolerability of PD-L1 Monoclonal Antibody Plus Lenalidomide in The Treatment of Colorectal Cancer

Henan Cancer Hospital

Phase 1 Unknown
33 enrolled
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡